tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Diabetes'

Nuvilex Applies to FDA for Orphan Drug Designation for Its Cell-in-a-Box Treatment for Pancreatic Cancer

Silver Spring, MD — October 13, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its Cell-in-a-Box® treatment for pancreatic cancer. If granted, Orphan Drug Designation in the United States will provide Nuvilex special development and commercial assistance from the FDA, including a 7 year period of marketing exclusivity. ...

Read More →
0

Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board

SILVER SPRING, MD., Oct. 6, 2014 — Nuvilex, Inc.Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of Nuvilex’s newly formed Scientific Advisory Board.

Dr. Lohr has been a full professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden, since 2007. He has served as Professor of Molecular Gastroenterology at the University ...

Read More →
0

Plandaí Biotechnology’s Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial

Plandaí Biotechnology’s Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial

Written by ι Stock Market Media Group Staff — September 10, 2014

Plandaí Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company’s green tea extract, Phytofare Catechin Complex, was clinically tested and compared to a commercially available green tea extract.  In the clinical trial, Plandaí’s Phytofare extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10. 

These results echo the USDA’s findings that were published in 2012.  The USDA ...

Read More →
0

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Written by ι Stock Market Media Group Staff — July 7, 2014

Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company’s “global development partners” at the 2014 BIO International Convention in San Diego.  One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex’s plans for treating diabetes.  This, of course, begs the question − is Nuvilex in line for ...

Read More →
0

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly

Written by ι Stock Market Media Group Staff — February 24, 2014

Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million “pot of money” to advance the company’s late-phase pancreatic cancer clinical trials.  Notice we said restricted shares, that’s right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex.  ...

Read More →
0

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment

Written by ι Stock Market Media Group Staff — December 5, 2013

Eli Lilly & Co. (NYSE: LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996.  Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company’s live-cell encapsulation based treatment for pancreatic cancer.  But, it may be another disease that has these two biotech’s going head ...

Read More →
0
Page 4 of 7 «...23456...»
ContactUs.com